Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Products under Development by Stage of Development | 7 | 1 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Products under Development by Therapy Area | 8 | 1 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Products under Development by Indication | 9 | 1 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Products under Development by Companies | 12 | 2 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Therapeutics Assessment | 14 | 7 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 2 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Companies Involved in Therapeutics Development | 21 | 5 |
| Clinuvel Pharmaceuticals Limited | 21 | 1 |
| Mallinckrodt Plc | 22 | 1 |
| Palatin Technologies, Inc. | 23 | 1 |
| Retrophin Inc. | 24 | 1 |
| SolaranRx, Inc. | 25 | 1 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drug Profiles | 26 | 17 |
| afamelanotide Drug Profile | 26 | 8 |
| AQB-565 Drug Profile | 34 | 1 |
| corticotropin Drug Profile | 35 | 2 |
| cosyntropin Drug Profile | 37 | 1 |
| CUV-9900 Drug Profile | 38 | 1 |
| PL-8176 Drug Profile | 39 | 1 |
| PL-8177 Drug Profile | 40 | 1 |
| SRX-1177 Drug Profile | 41 | 1 |
| VLRX-001 Drug Profile | 42 | 1 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Dormant Projects | 43 | 1 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Discontinued Products | 44 | 1 |
| Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Featured News &Press Releases | 45 | 16 |
| Aug 03, 2016: Clinuvel prepares New Drug Application for the treatment of erythropoietic protoporphyria | 45 | 1 |
| Jul 18, 2016: FDA accepts SCENESSE clinical data package for NDA submission | 46 | 2 |
| Jul 06, 2016: FDA awards SCENESSE Fast Track designation for treatment of EPP | 48 | 1 |
| Jul 05, 2016: Health Care Resource Use and Costs of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse | 49 | 1 |
| Jun 22, 2016: Clinuvel s SCENESSE launched in Europe | 50 | 1 |
| Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus | 50 | 2 |
| May 26, 2016: Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property | 52 | 1 |
| May 18, 2016: German Porphyria Expert Centres to start distribution of SCENESSE (afamelanotide 16mg) | 53 | 1 |
| May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome | 53 | 1 |
| Mar 24, 2016: NICE s technical team invited stakeholders with an interest in the treatment of erythropoietic protoporphyria | 54 | 1 |
| Feb 16, 2016: Clinuvel brief on European commercialisation | 55 | 1 |
| Feb 12, 2016: SCENESSE receives US FDA orphan designation for cutaneous porphyrias | 55 | 1 |
| Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study | 56 | 2 |
| Dec 03, 2015: Update on North American vitiligo program for SCENESSE | 58 | 1 |
| Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus | 59 | 2 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |
